Comparison of Gadobenate Dimeglumine-Enhanced Dynamic MRI and 16-MDCT for the Detection of Hepatocellular Carcinoma
Young Kon Kim1,
Chong Soo Kim1,
Gyong Ho Chung1,
Young-Min Han1,
Sang Yong Lee1,
Su Bin Chon1 and
Jeong Min Lee2
1 Department of Diagnostic Radiography, Chonbuk National University Hospital and
Medical School, Jeonju, South Korea.
2 Department of Radiology and Institute of Radiation Medicine, Seoul National
University Hospital, 28, Yongon-dong, Chongno-gu, Seoul 110-744, South
Korea.
View larger version (120K):
[in a new window]
|
Fig. 1A —63-year-old man with pathologically proven hepatocellular
carcinoma. Early arterial phase MDCT image shows no visible liver lesion.
|
|
View larger version (130K):
[in a new window]
|
Fig. 1B —63-year-old man with pathologically proven hepatocellular
carcinoma. Late arterial phase MDCT image shows subtly enhanced nodule in
segment V (arrow).
|
|
View larger version (127K):
[in a new window]
|
Fig. 1C —63-year-old man with pathologically proven hepatocellular
carcinoma. On delayed phase MDCT image, subtle enhancement of nodule in
B is shown as slight low attenuation (arrow).
|
|
View larger version (101K):
[in a new window]
|
Fig. 1D —63-year-old man with pathologically proven hepatocellular
carcinoma. Early arterial phase 3D dynamic MR image after administration of
gadobenate dimeglumine shows no visible liver lesion.
|
|
View larger version (111K):
[in a new window]
|
Fig. 1E —63-year-old man with pathologically proven hepatocellular
carcinoma. Late arterial phase MR image shows brightly enhanced nodule
(arrow) at same level as B.
|
|
View larger version (110K):
[in a new window]
|
Fig. 1F —63-year-old man with pathologically proven hepatocellular
carcinoma. On delayed phase MR image, brightly enhanced nodule shown in
E is depicted as low signal intensity (arrow), making the
nodule more conspicuous than on CT.
|
|
View larger version (123K):
[in a new window]
|
Fig. 2A —61-year-old man with surgically confirmed hepatocellular
carcinomas. Late arterial phase MDCT image shows area of subtle low
attenuation (arrow) in liver segment V.
|
|
View larger version (123K):
[in a new window]
|
Fig. 2B —61-year-old man with surgically confirmed hepatocellular
carcinomas. Delayed phase MDCT image also shows area of subtle low attenuation
(arrow) in same location as A; this finding was not regarded
as true lesion by any of the observers.
|
|
View larger version (110K):
[in a new window]
|
Fig. 2C —61-year-old man with surgically confirmed hepatocellular
carcinomas. Late arterial phase 3D dynamic MR image after administration of
gadobenate dimeglumine shows small enhanced nodule (arrow) in same
location as A.
|
|
View larger version (108K):
[in a new window]
|
Fig. 2D —61-year-old man with surgically confirmed hepatocellular
carcinomas. Equilibrium phase MR image obtained 3 min after contrast injection
shows small mass with low signal intensity (arrow); mass is more
conspicuous on this image than on B.
|
|
View larger version (117K):
[in a new window]
|
Fig. 3A —58-year-old man with surgically confirmed single
hepatocellular carcinoma. Late arterial phase MDCT image shows two nodular
enhancements in hepatic dome (arrows). Larger lesion was proven to be
hepatocellular carcinoma and other was proven to be pseudolesion. These two
lesions were correctly interpreted by all observers.
|
|
View larger version (106K):
[in a new window]
|
Fig. 3B —58-year-old man with surgically confirmed single
hepatocellular carcinoma. Late arterial phase 3D dynamic MR image after
administration of gadobenate dimeglumine shows three nodular enhancements in
hepatic dome, including hepatocellular carcinoma (large arrow) and
pseudolesion (upper small arrow), that were shown on MDCT (A).
This pseudolesion was correctly interpreted by all observers, but additional
enhancement (lower small arrow) of small pseudolesion was
misdiagnosed as a true lesion by all observers.
|
|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Copyright © 2006 by the American Roentgen Ray Society.
